Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Cash from Operations (2016 - 2025)

Tandem Diabetes Care's Cash from Operations history spans 13 years, with the latest figure at 9789000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 8.66% year-over-year to 9789000.0; the TTM value through Dec 2025 reached 9721000.0, down 140.13%, while the annual FY2025 figure was 9721000.0, 140.13% down from the prior year.
  • Cash from Operations reached 9789000.0 in Q4 2025 per TNDM's latest filing, up from 8264000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 34144000.0 in Q3 2021 to a low of 18326000.0 in Q1 2023.
  • Average Cash from Operations over 5 years is 7225850.0, with a median of 7582500.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: tumbled 232.8% in 2023, then soared 48589.09% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 19635000.0 in 2021, then plummeted by 70.36% to 5820000.0 in 2022, then tumbled by 223.99% to 7216000.0 in 2023, then skyrocketed by 248.52% to 10717000.0 in 2024, then fell by 8.66% to 9789000.0 in 2025.
  • Per Business Quant, the three most recent readings for TNDM's Cash from Operations are 9789000.0 (Q4 2025), 8264000.0 (Q3 2025), and 9496000.0 (Q2 2025).